Its most recent acquisition is a tiny company with an intriguing mid-stage type 2 diabetes therapy.
News & Analysis: Transition Therapeutics
Are these three stocks sells or belles? You be the judge!
Eli Lilly to pay Transition Therapeutics $7 million initially for the drug being developed to treat type 2 diabetes and accompanying obesity.